Latest Breaking News On - Professor paul de souza - Page 1 : comparemela.com

Noxopharm Ltd welcomes preliminary data on Veyonda drug trial

Noxopharm Ltd (ASX:NOX, OTC:NOXOF) has welcomed preliminary data of its oncology drug candidate Veyonda®, currently in trial in combination with Bristol.

United statesNew south walesWestern australiaBristol myers squibbNepean cancer centreAmerican society of clinical oncologyUniversity of sydneyNoxopharm ltdProfessor paul de souzaFoundation professorMedical oncologyWestern sydneyAmerican societyClinical oncology

Noxopharm Ltd s IONIC trial advances; Veyonda oncolytic drug passes safety milestone

Noxopharm Ltd s IONIC trial advances; Veyonda oncolytic drug passes safety milestone
proactiveinvestors.com.au - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com.au Daily Mail and Mail on Sunday newspapers.

New south walesGisela mautnerSafety steering committeeNoxopharm ltdBristol myers squibbSteering committeeNew southProfessor paul de souzaPaul de souza

Arbele Announces Phase 1 First-in-Human Study of CDH17xCD3 Bispecific T-Cell Engager for Treatment of Gastrointestinal Cancers

/PRNewswire/ Arbele, a clinical stage biopharmaceutical company, announces the successful dosing of the first patient in Australia in Phase I Study of.

Hong kongNew south walesDennis wongPrnewswire arbeleRoland leungSydney university medical schoolPhasei studyChief medical officerProfessor paul de souzaWestern sydney university medical schoolQueen maryInvestor contactDiana hayPortfolio director

Harbour BioMed Announces Dosing of First Patient in Australia for Phase Ib/IIa Clinical Study of its Next-Generation Anti-CTLA-4 Antibody

Share this article Share this article CAMBRIDGE, Mass. and ROTTERDAM, Netherlands and SUZHOU, China, May 11, 2021 /PRNewswire/ Harbour BioMed ( HBM , HKEX: 02142) today announced the dosing of the first patient in its part 2 of phase I (phase Ib/IIa) clinical study of its next-generation anti-CTLA-4 antibody, where Australian patients with metastatic or advanced melanoma, hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) and other type of tumors will be enrolled (study no. 4003.1). The objective of this study is to evaluate the safety, tolerability, PK/PD, and anti-tumor activity of HBM4003 as a single agent in multiple solid tumor types. The part 1 of phase I trial study results have been submitted to European Society of Medical Oncology (ESMO).

United kingdomJingsong wangEuropean society of medical oncologyEuropean societyMedical oncologyHarbour biomedProfessor paul de souzaஒன்றுபட்டது கிஂக்டம்ஐரோப்பிய சமூகம் ஆஃப் மருத்துவ புற்றுநோயியல்ஐரோப்பிய சமூகம்மருத்துவ புற்றுநோயியல்துறைமுகம் பயோமெட்